Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...

This stock can be held in an Investment ISA and an Investment Account ...

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, ...